Critical Illness, Glucose, Immune System and Related Disorders, Intensive Care Unit (ICU), Isotope Labeling, Metabolism, Sepsis
Conditions
Keywords
Immunometabolism, Stable Isotope Tracing, Immune Cell Metabolism, Intensive Care Unit, Critical Illness, Critical Care, Metabolism, Glucose, Sepsis, Septic Shock, Acute Respiratory Distress Syndrome, ARDS
Brief summary
The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Interventions
DRUG13C6-Glucose
Compounded as 5% 13C6-glucose in water and given intravenously over 2-4 hours at a total dose of 10-25 grams.
Sponsors
Vanderbilt University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults aged 18 or older * Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU * The participant or legally authorized representative must agree to the genetic analyses required as part of this study
Exclusion criteria
* Pregnant * Prisoner or in police custody * Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures * Hemoglobin less than 8 g/dL * Uncontrolled hyperglycemia (persistent blood glucose \>300 mg/dL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team * Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500 mL in an 8-week period * Unable to safely obtain vascular access required for study infusion and blood collection * Clinical instability or anticipated clinical care needs that would make the study procedure inappropriate at that time in the opinion of the Study Coordinator, PI, or treating ICU team * Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, might interfere with the study objectives * Any reason which, in the opinion of the study investigator, adds additional risk to the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 13C6-Glucose Uptake and Metabolism in Immune Cells | Up to 4 hours | Following 13C6-glucose infusion, peripheral blood immune cell populations will be magnetically isolated from collected blood and analyzed by mass spectrometry to quantify 13C6-glucose and downstream 13C-labeled metabolites. |
Countries
United States
Contacts
CONTACTMatthew T Stier, M.D., Ph.D.
Outcome results
None listed